In patients with advanced-stage classic Hodgkin lymphoma, a PFS benefit was seen at 3 years’ follow-up with N-AVD compared to BV-AVD.
R-CHOP plus ibrutinib, followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC DLBCL.
Standard-risk rel/ref multiple myeloma patients with benefit from earlier treatment with cilta-cel, rather than waiting for later lines of therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback